AgeneBio - Crunchbase Company Profile & Funding

Q: Where is AgeneBio's headquarters?

AgeneBio is located in Carmel, Indiana, United States.

Q: Who invested in AgeneBio?

AgeneBio has 5 investors including National Institutes of Health And Alzheimer's Drug Discovery Foundation.

Q: When was the last funding round for AgeneBio?

AgeneBio closed its last funding round on obfuscated from a Grant round.

Q: How much funding has AgeneBio raised to date?

AgeneBio has raised obfuscated.

Overview

AgeneBio

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About AgeneBio

CB Rank

58873

AgeneBio is a neuroscience pharmaceutical company developing treatments for diseases that impact memory.

Founded

obfuscation

Private

Grant

Carmel, Indiana, United States

1-10

agenebio.com

Biotechnology

Health Care

Neuroscience

Pharmaceutical

Funding Rounds

Grant

OBF

obfuscation

Grant

OBF

obfuscation

Debt Financing

OBF

obfuscation

Key People

Michela Gallagher: Founder & CEO

Details

Legal Name

AgeneBio Inc.

Operating Status

Active

Company Type

For Profit

Founders

Michela Gallagher

About the Company

AgeneBio is a neuroscience pharmaceutical company founded by Dr Michela Gallagher in 2008 that is focused on developing treatments for diseases that impact memory. The initial therapeutic targets are Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company is headquartered in Indianapolis but conducts research and

development work on a global basis utilizing partner relationships.

Phone Number

(410) 685-3000

Contact Email

gardiner.smith@agenebio.com

Diversity Spotlight

Women Founded

Women Led

Predictions & Insights

Growth Insight

See this Growth Insight

AgeneBio is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Products & Services

AGB101

A proprietary low-dose extended-release formulation of levetiracetam for treating mild cognitive impairment due to Alzheimer's disease by targeting hippocampal overactivity.

GABA A α5 Positive Allosteric Modulators

Investigational small molecule compounds targeting GABA-A α5 receptors to normalize brain function in neurological and psychiatric conditions including MCI due to Alzheimer's, schizophrenia, and autism.

Research & Development

AgeneBio is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant
obfuscated obfuscation	Grant - AgeneBio	2	obfuscated obfuscation	Alzheimer's Drug Discovery Foundation, National Institutes of Health	Grant

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
National Institutes of Health	Yes	Grant - AgeneBio	—
National Institutes of Health	Yes	Grant - AgeneBio	—
National Institutes of Health	Yes	Grant - AgeneBio	—
National Institutes of Health	Yes	Grant - AgeneBio	—
National Institutes of Health	Yes	Grant - AgeneBio	—